BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32430500)

  • 21. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
    Loberg MA; Bell RK; Goodwin LO; Eudy E; Miles LA; SanMiguel JM; Young K; Bergstrom DE; Levine RL; Schneider RK; Trowbridge JJ
    Leukemia; 2019 Jul; 33(7):1635-1649. PubMed ID: 30692594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.
    Ertz-Archambault N; Kosiorek H; Slack JL; Lonzo ML; Greipp PT; Khera N; Kelemen K
    Biol Blood Marrow Transplant; 2017 May; 23(5):782-789. PubMed ID: 28189903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
    Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach.
    Homaei Hadad E; Pezeshki SMS; Shahrabi S; Saki Malehi A; Saki N
    Expert Rev Hematol; 2020 Nov; 13(11):1289-1301. PubMed ID: 32886563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
    Higgins A; Shah MV
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
    Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
    Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
    Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomics of MPN progression.
    Patel AA; Odenike O
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):440-449. PubMed ID: 33275731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute myeloid leukemia: 2014 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2014 Nov; 89(11):1063-81. PubMed ID: 25318680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.
    Beer PA; Ortmann CA; Stegelmann F; Guglielmelli P; Reilly JT; Larsen TS; Hasselbalch HC; Vannucchi AM; Möller P; Döhner K; Green AR
    Haematologica; 2010 Dec; 95(12):2153-6. PubMed ID: 20823136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerated and Blast Phase Myeloproliferative Neoplasms.
    Jain T; Rampal RK
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):325-335. PubMed ID: 33641872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
    Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
    Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
    Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
    Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.